Professional Documents
Culture Documents
Tissue Biomechanics
Philippe K. Zysset
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
What is Biomechanics?
Motivation
Osteoporosis
FACTS IN AUSTRIA
750’000 patients
1 out of 3 women
1 out of 7 men
12’000 hip fx a year
Chronic pain and impair.
20% mortality after 70
12’000 Euros per hip fx
Koeck et al., Wiener Klin Wochen, Hip fracture
2001.
Osteoporosis
FACTS IN AUSTRIA
750’000 patients
1 out of 3 women
1 out of 7 men
12’000 hip fx a year
Chronic pain and impair.
20% mortality after 70
12’000 Euros per hip fx
Koeck et al., Wiener Klin Wochen, Bone mass as a function of age
2001.
Bone Mechanics
Residual stresses
Elasticity
Viscoelasticity Poroelasticity
Damage
Initiation Accumulation
Strength
Impact Toughness Fatigue
The Bedside
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
Type I collagen
Apatite platelets
Water
Non-collagenous proteins
Lamellar Organization
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
Indentation Principle
P P
t h
t t
t h
I 4π
E (S, a3 ) = Z 2π
B (t(γ), S) : [a3 ⊗ a3 ]
−1
p dγ
0 (a1 /a2 ) cos2 γ + (a2 /a1) sin2 γ
M min max
20
10
m3
0
m3
-10
-20
-10
-10
m1
0
0
m1 m2
m2 10 10
-10
10 0
10
0
-10
50.2
20
32.6
-20
20
10
-10
-20
39.5
10
-10
31.8
-20
-10
0
10
20
Trabecular tissue
10
-10
20
43.5
10
-10
39.
-20
-10
0
10
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
Fabric
3
X 3
X
i
M= mi M = mi (mi ⊗ mi )
i =1 i =1
Fabric-based Elasticity
3
X 1
C(ρ, M) = Mi ⊗ Mi
ǫ ρk mi2l
i =1 0
3
X ν0
− (Mi ⊗ Mj + Mj ⊗ Mi )
i <j=1 0
ǫ ρ mil mjl
k
3
X 1
+ (Mi ⊗Mj + Mj ⊗Mi )
i <j=1
2µ0 ρk mil mjl
Fabric-based Elasticity
2000
FF
F F
adj. R2 =0.942 FT FF
T FTFF F T
1000 FTTFFT
F
T F FT
RRFTTRT
T
T
RTTT TR
500 TTTRTTRTT
20
O Multiaxial
10
10 20 50 100 200 500 1000 2000
Experimental stiffness @MPaD
Validation Experiment
MicroCT at 20 µm
Mechanical testing
Nanoindentation
Voxel-based FEA
Sub-region FEA
Results
FE Modulus @MPaD
Tissue Modulus @GPaD
25
20 2000
15
10
1500
Mean±SD=21.1±1.0 @GPaD
5 1000
0
0 1 2 3 4 5 6 7
Samples 500 R2=0.978
0
0 500 1000 1500 2000 2500 3000 3500
Experimental Modulus @MPaD
Sensitivity Analysis
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
pQCT Resolution
Results
10 000 10 000
Ultimate force @ND
0 0
0 50 100 150 200 250 300 0 2000 4000 6000 8000 10 000
microFE stiffness @kNmmD FE ultimate force @ND
Outline
1 Introduction
3 Tissue
4 µCT
5 pQCT
6 HR-QCT
QCT Resolution
Multicenter
44 post-menopausal women
(68±6.7 y.o.)
Teriparatide 20µg/day
DXA L1-L4
HRQCT T12
0,6,12,24 months
Model parameters:
Cubic elements of 1.3mm
Top and bottom PMMA layers
Density-based mat. properties
Homogeneous I-S architecture
Axial loading
Output variables:
Stiffness:=load/displacement
Strength:=maximum load
Distribution of damage Chevalier et al., Comput
Method Biomech, 2007.
Results
3500
3000
24 Mo
2500
Force @ND
12 Mo
2000
1500 6 Mo
1000
Baseline
500
0
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
Increase of strength in %
*
*
100 *
*
INCREASE @%D
50
*
-50
6 12 24
MONTHS
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Results
24Mo
2000
Force @ND
1500
1000
24 Months
500
Baseline
0 Base
0.0 0.2 0.4 0.6 0.8 1.0
Displacement @mmD
Acknowledgments
Acknowledgments
AO Foundation, Switzerland - AO Research Institute, Switzerland - CAE, Austria -
Celtis, Austria - Eli Lilly & Company, Europe - ESRF, France - ETH Lausanne,
Switzerland - ETHZürich, Switzerland - FWF, Austria - Inselspital Bern, Switzerland -
Institut für Unfallchirurgische Forschung und Biomechanik, Germany - Kuros
Biosurgery, Switzerland - Laboratoire d’Imagerie Paramétrique, France - Ludwig
Boltzmann Institut für Experimentelle und Klinische Traumatologie, Austria - Ludwig
Boltzmann Institut für Osteologie, Austria - Ludwig-Maximilians Universität München,
Germany - Max-Planck-Institut für Kolloid und Grenzflächen Forschung, Germany -
Med Uni Wien, Austria - Paracelsus Medizinische Universität, Austria - Politecnico di
Milano, Italy - Sanofi-Aventis, USA - Technical University Prague, Czech Republic -
Technische Universität Hamburg-Harburg, Germany - Universität Bern, Switzerland -
Universitätsklinik Schleswig-Holstein, Germany - Universitätsmedizin Berlin, Germany
- University of Leeds, Great Britain, Veterinärmedizinische Universität Wien, Austria -
VINforce, Austria